Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study

被引：1

作者：

le Coutre, Philipp D. ^{[1
]}

Turkina, Anna ^{[2
]}

Kim, Dong-Wook ^{[3
]}

Ceglarek, Bernadeta ^{[4
]}

Alimena, Giuliana ^{[5
]}

Al-Ali, Haifa Kathrin ^{[6
]}

Shen, Zhixiang ^{[7
]}

Jootar, Saengsuree ^{[8
]}

Smith, Graeme ^{[9
]}

De Souza, Carmino Antonio ^{[10
,11
]}

Dorlhiac-Llacer, Pedro Enrique ^{[12
]}

Rizzieri, David A. ^{[13
]}

Szczudlo, Tomasz ^{[14
]}

Berton, Myriam ^{[15
]}

Wang, Jim ^{[16
]}

Wang, Si-Tien ^{[17
]}

Nicolini, Franck Emmanuel ^{[18
]}

机构：

[1] Humboldt Univ, Charite, Dept Hematol & Oncol, Berlin, Germany

[2] Minist Publ Hlth Russia, Hematol Res Ctr, Moscow, Russia

[3] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[4] Inst Hematol & Transfufzjol, Warsaw, Poland

[5] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy

[6] Univ Leipzig, Dept Hematol Oncol, Leipzig, Germany

[7] Shanghai Ruijin Hosp, Shanghai, Peoples R China

[8] Mahidol Univ, BMT Program, Ramathibodi Hosp, Bangkok 10700, Thailand

[9] Dept Haematol, Leeds, W Yorkshire, England

[10] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, Sao Paulo, Brazil

[11] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, Campinas, SP, Brazil

[12] FMUSP, Hosp Clin, Sao Paulo, Brazil

[13] Duke Univ, Med Ctr, Durham, NC USA

[14] Novartis Pharmaceut, Florham Pk, NJ USA

[15] Novartis Pharmaceut, Basel, Switzerland

[16] Novartis Pharmaceut, E Hanover, NJ USA

[17] Anal Grp Inc, Boston, MA USA

[18] Hop Edouard Herriot, Lyon, France

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1272 / 1273

页数：2

共 50 条

[41] Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
Cortes, J.
Kim, D-W
Raffoux, E.
Martinelli, G.
Ritchie, E.
Roy, L.
Coutre, S.
Corm, S.
Hamerschlak, N.
Tang, J-L
Hochhaus, A.
Khoury, H. J.
Bruemmendorf, T. H.
Michallet, M.
Rege-Cambrin, G.
Gambacorti-Passerini, C.
Radich, J. P.
Ernst, T.
Zhu, C.
Van Tornout, J. M. A.
Talpaz, M.
LEUKEMIA, 2008, 22 (12) : 2176 - 2183
[42] Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
J Cortes
D-W Kim
E Raffoux
G Martinelli
E Ritchie
L Roy
S Coutre
S Corm
N Hamerschlak
J-L Tang
A Hochhaus
H J Khoury
T H Brümmendorf
M Michallet
G Rege-Cambrin
C Gambacorti-Passerini
J P Radich
T Ernst
C Zhu
J M A Van Tornout
M Talpaz
Leukemia, 2008, 22 : 2176 - 2183
[43] Safety and Efficacy of Frontline Nilotinib (Nb) for Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Diabetic Patients (pts)
Shoukier, Mahran
Kantarjian, Hagop M.
Jabbour, Elias
Quintas-Cardama, Alfonso
Estrov, Zeev
Kadia, Tapan
Borthakur, Gautam
Garcia-Manero, Guillermo
Kornblau, Steven M.
Burton, Elizabeth M.
O'Brien, Susan
Cortes, Jorge E.
BLOOD, 2011, 118 (21) : 1189 - 1189
[44] Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP)
Jabbour, E.
le Coutre, P.
Baccarani, M.
Bhalla, K.
Ossenkoppele, G. J.
Hochhaus, A.
Gattermann, N.
Haque, A.
Weitzman, A.
Kantarjian, H.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[45] Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis
Giles, Francis J.
Rea, Delphine
Baccarani, Michele
Cross, Nicholas C. P.
Luis Steegmann, Juan
Griskevicius, Laimonas
le Coutre, Philipp
Coriu, Daniel
Petrov, Ljubomir
Ossenkoppele, Gert J.
Mahon, Francois-Xavier
Mueller, Martin C.
Hellmann, Andrzej
Porkka, Kimmo
Bruemmendorf, Timothy H.
Gastl, Gunther
Tubazio, Viviana
Pellegrino, Angela
Dezzani, Luca
Rosti, Gianantonio
Hochhaus, Andreas
BLOOD, 2015, 126 (23)
[46] Analysis of glucose profiles in imatinib-resistant or intolerant chronic myelogenous leukemia (CML) patients (pts)treated with nilotinib: Lack of correlation between glucose levels and nilotinib efficacy.
le Coutre, Philipp
Giles, Francis J.
Hochhaus, Andreas
Martinelli, Giovanni
Wang, Jim
Passos, Vanessa
Kayath, Marcia
Baccarani, Michele
Kantarjian, Hagop M.
BLOOD, 2007, 110 (11) : 219B - 219B
[47] THE BUDGET IMPACT ANALYSIS OF NILOTINIB IN THE SECOND-LINE TREATMENT OF IMATINIB-RESISTANT OR INTOLERANT CHRONIC MYELOID LEUKEMIA
Huang, C.
Shen, L.
Liu, Y.
VALUE IN HEALTH, 2018, 21 : S96 - S96
[48] Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Branford, Susan
Kim, Dong-Wook
Soverini, Simona
Gottardi, Enrico
Beppu, Lan
Mueller, Martin C.
Haque, Ariful
Shou, Yaping
Woodman, Richard C.
Kantarjian, Hagop M.
Martinelli, Giovanni
Radich, Jerald P.
Saglio, Giuseppe
Hughes, Timothy P.
Hochhaus, Andreas
BLOOD, 2009, 114 (22) : 1275 - 1276
[49] Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data
Kantarjian, Hagop M.
Jabbour, Elias
Giles, Francis J.
Bhalla, Kapil N.
Pinilla-Ibarz, Javier
Larson, Richard A.
Gattermann, Norbert
Ottmann, Oliver G.
Wang, Jim
Woodman, Richard C.
Baccarani, Michele
le Coutre, Philipp D.
Cortes, Jorge
BLOOD, 2009, 114 (22) : 1278 - 1279
[50] RAPID INITIAL DECLINE IN BCR-ABL LEVELS IS ASSOCIATED WITH SUPERIOR RESPONSES IN IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB
Stein, A.
Shou, Y.
Bottino, D.
Chia, Y. L.
Woodman, R.
Martinelli, G.
Hughes, T.
Mueller, M.
Beppu, L.
Gottardi, E.
Branford, S.
Soverini, S.
Goh, H.
Hochhaus, A.
Kim, D.
Saglio, G.
Radich, J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 56 - 56

← 1 2 3 4 5 →